Evaluating the regulatory function of non-coding autism-associated single nucleotide polymorphisms on gene expression in human brain tissue.
Top autism GWAS SNPs do not reliably change gene output in post-mortem brain tissue.
01Research in Context
What this study did
Pugsley et al. (2024) asked a simple question. Do the non-coding SNPs flagged by big autism GWAS actually change gene output in human brain tissue?
They tested post-mortem samples from people with autism and matched controls. Then they looked for any SNP that reliably up- or down-regulated nearby genes.
What they found
After strict correction for multiple tests, zero SNPs showed a clear effect. No genotype-by-diagnosis interactions either.
In plain words: the top genetic hits from GWAS do not act like volume knobs for gene expression in the adult brain.
How this fits with other research
The result lines up with a long line of null brain studies. G. et al. (2006) saw normal S6 phosphorylation, Cioana et al. (2020) saw normal IGF-1, and Sakurai et al. (2008) saw no coding-variant signal in SLC6A4. All used post-mortem tissue and came up empty.
Fatemi et al. (2014) looks like a contradiction—they found lower GABAA receptor protein in the same frontal area. The difference is target choice. Hossein measured the protein itself; Kealan tested whether GWAS SNPs control the dials. The protein can be low even if the SNPs are not the reason.
Granieri et al. (2020) offers a positive mirror. They linked CD38, OXTR, PRL and IL-10 SNPs to GI issues in autism. The takeaway: SNP effects may show up in the gut, not the brain, so phenotype choice matters when you hunt biomarkers.
Why it matters
For BCBAs this means: do not wait for a gene-expression test to guide therapy. The current genetic flags are not proven levers. Keep focusing on skill-based assessment and reinforcement. Let neurologists track future biomarkers; you track behavior.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Drop any reference to 'autism risk SNPs control brain genes' from parent handouts—stick to data you can see in session.
02At a glance
03Original abstract
Common variants account for most of the estimated heritability associated with autism spectrum disorder (autism). Although several replicable single nucleotide polymorphisms (SNPs) for the condition have been detected using genome-wide association study (GWAS) methodologies, their pathophysiological relevance remains elusive. Examining this is complicated, however, as all detected loci are situated within non-coding regions of the genome. It is therefore likely that they possess roles of regulatory function as opposed to directly affecting gene coding sequences. To bridge the gap between SNP discovery and mechanistic insight, we applied a comprehensive bioinformatic pipeline to functionally annotate autism-associated polymorphisms and their non-coding linkage disequilibrium (i.e., non-randomly associated) partners. We identified 82 DNA variants of probable regulatory function that may contribute to autism pathogenesis. To validate these predictions, we measured the impact of 11 high-confidence candidates and their GWAS linkage disequilibrium partners on gene expression in human brain tissue from Autistic and non-Autistic donors. Although a small number of the surveyed variants exhibited measurable influence on gene expression as determined via quantitative polymerase chain reaction, these did not survive correction for multiple comparisons. Additionally, no significant genotype-by-diagnosis effects were observed for any of the SNP-gene associations. We contend that this may reflect an inability to effectively capture the modest, neurodevelopmental-specific impact of individual variants on biological dysregulation in available post-mortem tissue samples, as well as limitations in the existing autism GWAS data.
Autism research : official journal of the International Society for Autism Research, 2024 · doi:10.1002/aur.3101